PDCD1 and diabetes mellitus: Finally, we found that patients on immunotherapy with diabetes had a higher number of documented neuropathies associated with PD-1 inhibitor exposure compared to non-diabetic patients, although this finding was not statistically significant (Table 1; OR 1.116, 95% CI 0.945–1.320, p = 0.1967).